256 papers
Cancer biology explores the complex ways cells grow out of control, investigating the genetic mutations and environmental factors that drive tumor formation. This field seeks to understand how healthy cells transform into malignant ones and how these rogue cells spread throughout the body. By decoding these fundamental mechanisms, researchers aim to develop more effective treatments that target the disease at its source while sparing healthy tissue.
At Gist.Science, we process every new preprint published in this category directly from bioRxiv to ensure you stay ahead of the curve. Our team provides both accessible plain-language overviews and detailed technical summaries for each study, bridging the gap between raw research data and practical understanding. Whether you are a specialist or a curious reader, our goal is to make these critical findings clear and actionable.
Below are the latest papers in cancer biology, offering fresh insights into the ongoing fight against this disease.
This paper presents a novel in vitro fluidic model that successfully mimics bidirectional interactions between primary breast cancer and lung metastatic sites, demonstrating altered cell behaviors and validating the system's ability to replicate in vivo colonization patterns observed in mouse models.
This study demonstrates that G34-mutant pediatric diffuse hemispheric gliomas can be targeted by HDL nanoparticles co-delivering CpG dinucleotides to stimulate NF-κB-mediated immune responses and olaparib to exploit DNA repair deficiencies, thereby offering a promising therapeutic strategy for these aggressive tumors.
This paper presents a refined virtual cohort framework that generates over 10,000 simulated mice to capture treatment response variability and stratify individuals, demonstrated through its application to gemcitabine and OT-1 cell therapy in a murine bladder cancer model.
This study demonstrates that growth hormone drives triple-negative breast cancer progression by activating DRP1-mediated mitochondrial fission, which is essential for linking metabolic reprogramming toward glycolysis with cell proliferation and the modulation of the inflammatory tumor microenvironment.
This study utilizes an integrated multi-omics approach on bioengineered, vascularized pancreatic cancer spheroids to characterize a therapy-resistant, immunosuppressive tumor niche that recapitulates patient heterogeneity and provides a powerful translational platform for developing new PDAC treatments.
By analyzing RNA sequencing data from 721 renal cell carcinoma samples, this study identifies a robust 13-gene transcriptomic signature characterized by loss of epithelial identity and mitochondrial dysregulation that accurately predicts intravascular tumor extension.
This study employs high-stringency computational analysis to predict a high-affinity interaction between the plant-derived *Moringa oleifera* miR156 and the human CDK4 3'UTR, suggesting a potential cross-kingdom mechanism for regulating cell-cycle progression in triple-negative breast cancer.
This study demonstrates that depleting the oncogenic factor HSF1 in malignant cells triggers a catastrophic proteomic imbalance and amyloidogenesis that can be exploited for tumor suppression, whereas HSF1 is dispensable for non-transformed cells, highlighting a novel therapeutic strategy to combat malignancy by provoking proteomic catastrophe.
This study demonstrates that canonical NF-κB signaling constrains RAS-driven B-cell acute lymphoblastic leukemia by inducing a mature B-cell receptor state incompatible with oncogenic RAS activity, thereby triggering apoptosis in RAS-mutated cells and explaining the mutual exclusivity of these pathway alterations in leukemia.
This study evaluates the clinical feasibility of evolutionary therapy for metastatic non-small cell lung cancer by demonstrating that while higher containment levels and dynamic protocols can improve outcomes, their success critically depends on minimizing measurement errors and appointment delays, with single-bound protocols proving more robust to these real-world clinical constraints.